Skip to Main Content

Paper Details

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Clin Infect Dis
3
2023
CDI, Clostridioides difficile, Clostridioides difficile Infection, Clostridioides difficile infection, Patients, SER-109, creatinine, fecal microbiota spores, immunosuppression, malignancy, participants, patients, placebo, rCDI
Author NameAffiliation
Colleen S KraftEmory University
Barbara H McGovernClinical Development
  • 1 - 2

Datasets

Release 1.2